Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

19.91USD
10:17am EST
Change (% chg)

$0.92 (+4.84%)
Prev Close
$18.99
Open
$19.38
Day's High
$19.91
Day's Low
$19.34
Volume
4,244
Avg. Vol
37,831
52-wk High
$23.35
52-wk Low
$8.00

Latest Key Developments (Source: Significant Developments)

Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Protagonist Therapeutics Inc : :Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200.Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen.  Full Article

Protagonist Therapeutics Q3 ‍net loss per share $0.29​
Monday, 6 Nov 2017 04:01pm EST 

Nov 6 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update.Protagonist Therapeutics Inc qtrly ‍net loss per share attributable to common stockholders was $0.29​.  Full Article

Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share
Wednesday, 11 Oct 2017 10:26pm EDT 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Prices public offering of common stock.Says public offering of 3.53 million common shares priced at $17.00 per share.  Full Article

Protagonist Therapeutics announces proposed public offering of common stock
Wednesday, 11 Oct 2017 04:01pm EDT 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces proposed public offering of common stock.Protagonist Therapeutics -to use proceeds to fund clinical research, development of co's three therapeutic candidates, PTG-100, PTG-200, and PTG-300​.  Full Article

Protagonist Therapeutics announces preliminary phase 1 study results with PTG-300
Wednesday, 20 Sep 2017 08:00am EDT 

Sept 20 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces preliminary phase 1 study results with novel hepcidin mimetic, PTG-300.Protagonist Therapeutics Inc - ‍expect to report final top line results of amended PTG-300 study in Q4 of 2017​.Protagonist - ‍PTG-300 showed dose-dependent increase in blood exposure, was well tolerated, with no serious adverse events or dose-limiting toxicities​.  Full Article

Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​
Friday, 1 Sep 2017 04:51pm EDT 

Sept 1 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​.  Full Article

Protagonist Therapeutics announces closing of Janssen license
Thursday, 24 Aug 2017 04:01pm EDT 

Aug 24 (Reuters) - Protagonist Therapeutics Inc ::Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment.Protagonist Therapeutics - ‍following closure of transaction, co received upfront payment of $50 million originally announced by two cos as part of agreement.Protagonist Therapeutics Inc - ‍PTG-200 is expected to enter phase 1 clinical testing before end of 2017​.  Full Article

Protagonist Therapeutics reports Q2 loss per share of $0.89
Tuesday, 8 Aug 2017 04:17pm EDT 

Aug 8 (Reuters) - Protagonist Therapeutics Inc :Protagonist therapeutics reports second quarter 2017 financial results and business highlights.Protagonist therapeutics inc - qtrly ‍net loss per share attributable to common stockholders, basic and diluted $ 0.89.Q2 earnings per share view $-0.86 -- Thomson Reuters I/B/E/S.  Full Article

Protagonist Therapeutics says will be responsible for conduct of Phase 1 clinical trial for PTG-200
Tuesday, 30 May 2017 07:40am EDT 

May 30 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics Inc says co will be responsible, at its own expense, for conduct of Phase 1 clinical trial for PTG-200 - SEC filing.Protagonist Therapeutics Inc - Janssen will be responsible for conduct of a phase 2 clinical trial for ptg-200 in CD.Protagonist therapeutics -development costs for phase 2 clinical trial to be shared between parties on an 80 percent Janssen and 20 percent protagonist basis.Protagonist Therapeutics - with funding from this collaboration, co believes it has financial resources to fund all activities until middle of 2019.  Full Article

Protagonist Therapeutics reports qtrly net loss per share attributable to common stockholders $0.84
Wednesday, 10 May 2017 04:01pm EDT 

May 10 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics reports first quarter 2017 financial results.Qtrly net loss per share attributable to common stockholders $0.84.Protagonist Therapeutics - Expects current capital resources will be sufficient to fund operations through PTG-100 phase 2B top-line data.  Full Article

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage: